B2Broker Invests $5M in B2Trader - The Next-Gen Brokerage Platform
25.3.2024 21:15:00 EET | Business Wire | Press release
The crypto market is on an exciting growth journey, with Bitcoin hitting all-time highs and the total crypto market cap exceeding $2.37T. This coincides with the introduction of MiCA regulation, effective June 30, 2024, and followed by another wave on December 30, 2024, aiming to increase credibility and transparency, fostering wider crypto adoption.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240325324392/en/
B2Broker releases B2Trader, an industry-leading crypto spot brokerage solution. (Graphic: Business Wire)
With over 20,000 coins and tokens and a user base of over 300 million traders, compared to the FX market's 128 currency pairs and estimated 50 million traders, crypto is emerging as a more appealing trading option. Its expansion is fueled by its broad adaptation across finance, fintech, payments, and other sectors. Introducing innovative business models through technologies like L2 solutions and blockchain protocols.
To meet the booming crypto trading demand, brokerages are actively seeking solutions to enter the market. And in response, B2Broker announces the release of the B2Trader Brokerage Platform (BBP), a crypto spot broker solution designed to help businesses tap into this growing trend and start generating revenue faster than ever!
Who Can Benefit from B2Trader?
B2Trader is a powerful solution for crypto brokers (CFD and Derivatives), OTC brokers, FOREX brokers, multi-asset and multi-market brokers, market makers, liquidity providers, payment systems, and even banks to follow the market trends and enter the fastest-growing industry.
Here’s how each business model is able to utilise BBP:
FOREX Brokers
B2Trader can be an excellent addition to any FX broker. Along with the traditional trading platforms (MT4, MT5, cTrader, etc.) that mainly handle assets like FX, crypto, equity indices, and precious metals for margin trading or in the form of CFDs, you can add B2Trader to offer crypto spot trading exclusively, attract a new segment of crypto traders interested in physical delivery or ownership, and generate revenue through commissions, markups, and effective risk management.
Additionally, BBP offers a solution for regulated FX brokers to separate their digital asset trading under a different license, promoting strategic diversification and maintaining a competitive advantage in today’s market.
Crypto Brokers
Brokers focusing on crypto CFDs, using crypto as collateral, and offering a mix of FX and crypto CFDs can use B2Trader to enhance existing solutions with crypto spot trading.
Given the competitive nature of client retention and acquisition, the absence of crypto spot trading options could lead clients to seek services elsewhere. Thus, integrating B2Trader is a strategic advantage for brokerages, allowing them to adapt to market trends swiftly, offer much-demanded crypto spot trading, and meet client expectations.
Market Makers
Market makers can use B2Trader to access multiple exchanges, consolidate liquidity efficiently, achieve competitive spreads, optimise pricing, and enable smart routing execution across different venues.
Liquidity Providers
Adding cryptocurrencies to your asset offerings greatly boosts your appeal to brokers, hedge funds and professional traders. B2Trader streamlines this process, equipping you with the essential tools to expand your market reach and accelerate your earnings.
EMIs, Payment Systems, and Banks
For EMIs, PSPs, and banks, B2Trader provides a strategic edge by enabling diverse asset management, monitoring, and liquidity pool creation. It allows these entities to add crypto services to their existing operations, net all transactions, offer crypto accounts, and enable instant swaps.
BBP opens unlimited opportunities as your gateway to crypto and its booming trends. With its comprehensive API and a complete set of essential components and modules, B2Trader seamlessly integrates into any business model.
High-Speed, High-Efficiency, High-Tech
B2Trader is designed for the Enterprise scale of brokers to serve modern financial markets. Even in its most basic setup, it handles 3000 trading instruments and processes up to 3000 requests per second. It offers real-time market data, updates every 100 ms and ultra-fast order execution starting from 1 ms. This can be improved further by enhancing cloud resources and computing.
"Today, B2Broker is a leading name in the FinTech industry. We began operating in the FOREX industry in 2014 and have been developing solutions for the crypto industry since 2017. B2Broker has earned multiple awards and recognitions, and our years of experience have allowed us to understand what the market needs exactly.
That's why we created B2Trader. It's our answer to the changing trends in finance. We have poured 18 months of hard work and over $5 million into B2Trader. BBP is built by our dedicated in-house team of 40 engineers, each contributing to a solution that truly meets the demands of today's brokers. In the next 12 months, we are planning to double the team and enhance our offerings even further!"
— Arthur Azizov, CEO and Founder of B2Broker
Cutting-Edge Technology Stack
BBP focuses on reliability, scalability, and security, using the latest tools and protocols. It is hosted on AWS for its dependable infrastructure, reducing hardware risks. It utilises MongoDB and Amazon Redshift for data management and includes TradingView for market insights.
Kubernetes and Docker support scalable deployments, while CloudFlare provides DDoS protection. The FIX protocol boosts B2Trader's efficiency and reliability.
Powerful Integrations
Developed by B2Broker, B2Trader offers powerful integrations. B2Broker offers a comprehensive suite of products, including a trading platform, OMS, pre-trade and post-trade control, liquidity management system, Trading User Interface, CRM, back office, blockchain wallets for processing and collecting coins/tokens, blockchain management system for automatic payouts and settlements, mobile applications, technical documentation, REST and FIX API protocols, advanced White Label options, and much more.
Additionally, integrated with Marksman, a crypto liquidity distribution engine, B2Trader streamlines administration and ensures market updates with the latest data.
With Marksman, crypto brokers swiftly link to top exchanges by inputting API credentials after opening an account. This allows brokers to create diverse liquidity pools from various exchanges, assign specific execution and routing rules, and establish failover protocols for both the pairs and the liquidity pools.
B2Trader is available as a turnkey solution or for integration with any CRM via REST API. Contact the sales team or your account manager, try out the free demo, and launch your crypto spot broker within a week!
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240325324392/en/
Contact information
sales@b2broker.net
+44 208 068 8636
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom